Qlife enters fully funded feasibility agreement with global pharma company
The feasibility study evaluates a specific biomarker for a therapeutic application, potentially leading to long-term collaboration.
See the latest news and media coverage for Qlife. We track all announcements, press releases, and industry mentions in real time, all in one place.
Last updated
In short: Qlife secured a fully funded feasibility agreement with a global pharma company and advanced its Egoo Health platform through clinical validations.
The feasibility study evaluates a specific biomarker for a therapeutic application, potentially leading to long-term collaboration.
The meeting adopted financial statements, granted discharge, re-elected board, and authorized share issuance.
Revenue was kSEK 21, EBITDA loss kSEK -5,502, and net loss kSEK -6,225.
The report is available for download on Qlife's website or can be ordered via info@egoo.health.
On 22 January 2026, Qlife Holding AB ("Qlife" or the "Company") announced a rights issue of approximately SEK 31.4 million, which was approved by an...
Qlife Holding AB ("Qlife" or the "Company"), a pioneer in clinical-grade home diagnostics, today provides a business update covering recent milestones, ongoing progress, and priorities...
Qlife Holding AB ("Qlife" or the "Company") publishes an information document regarding the Company's new share issue with preferential rights for existing shareholders of approximately...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive...
Track Qlife and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.